Stockscreener 앱 받기
3.09
0.00%
0.00
시간 외 거래:
3.09
전일 마감가:
$3.09
열려 있는:
$3.07
하루 거래량:
1.99M
Relative Volume:
1.05
시가총액:
$183.32M
수익:
$1.04B
순이익/손실:
$111.90M
주가수익비율:
1.5684
EPS:
1.9701
순현금흐름:
$205.80M
1주 성능:
-3.74%
1개월 성능:
-1.59%
6개월 성능:
-73.77%
1년 성능:
-68.60%
1일 변동 폭
$3.07
$3.2555
1주일 범위
$3.02
$3.27
52주 변동 폭
$2.77
$15.55
Embecta Corp Stock (EMBC) Company Profile
명칭
Embecta Corp
전화
(862) 401-0000
주소
300 KIMBALL DRIVE, PARSIPPANY
Compare EMBC vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EMBC
Embecta Corp
|
3.09 | 185.70M | 1.04B | 111.90M | 205.80M | 1.9701 |
ISRG
Intuitive Surgical Inc
|
402.18 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
141.61 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.14 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.42 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
186.29 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Embecta Corp Stock (EMBC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Neutral |
| 2024-12-02 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-27 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-10-20 | 개시 | Wolfe Research | Peer Perform |
| 2023-01-06 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-09-08 | 개시 | BTIG Research | Neutral |
| 2022-08-01 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-06-21 | 개시 | BofA Securities | Underperform |
모두보기
Embecta Corp 주식(EMBC)의 최신 뉴스
Embecta Corp. Announces Appointment of Nimish Muzumdar to Senior Vice President and President, North America, Effective June 15, 2026 - marketscreener.com
Embecta Corp. Appoints Nimish Muzumdar as Senior Vice President and President, North America - Quiver Quantitative
New embecta North America chief once ran a $1B generics division - Stock Titan
EMBC Investors Have Opportunity to Join Embecta Corp. Fraud Investigation with the Schall Law Firm - The AI Journal
EMBC News | EMBECTA CORP (NASDAQ:EMBC) - ChartMill
Packaging update regarding BD pen needles and insulin syringes - retailpharmacymagazine.com.au
EMBC Q1 2026 Earnings: EPS Miss Sends Shares LowerEarnings Sentiment Score - newsline.com
EMBC Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesEPS Surprise History - newsline.com
EMBC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Embecta Corp. (EMBC) Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Cost Headwinds PersistCash Flow Report - newsline.com
Mizuho cuts Embecta stock price target on weak US sales performance - Investing.com
River Road Asset Management, LLC Sells Out Position in Embecta C - GuruFocus
Embecta Corp. (EMBC) grants 30,000 shares to VP, Chief Accounting Officer - Stock Titan
embecta to Participate in Investor Events - The Manila Times
Embecta to Participate in Investor Events - marketscreener.com
EMBC Technical Analysis & Stock Price Forecast - Intellectia AI
Embecta faces US reset as CEO bets on GLP-1, Owen Mumford diversification - MSN
EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp. - GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Embecta Corp. - GlobeNewswire
Embecta Corp. (EMBC) Shows Modest Rebound as Shares Trade Near Support LevelsMoney Flow - thelegaladvocate.com
Law firm investigates Embecta after shares plunge 58% on weak Q2 results and lowered guidance - Pluang
Embecta (NYSE: EMBC) Schedule 13G/A — River Road reports 0 shares - Stock Titan
Embecta To Go Ex-Dividend On May 28th, 2026 With 0.01 USD Dividend Per Share - Moomoo
EMBC - Finviz
Embecta Corp. (EMBC) Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains UndisclosedEPS Guidance Update - thelegaladvocate.com
EMBC PE Ratio & Valuation, Is EMBC Overvalued - Intellectia AI
Embecta acquires Owen Mumford for $172.6m - MSN
Embecta (EMBC) Faces Target Cut Amid Weakening Medtech SentimentAnalyst Drop Coverage - newsline.com
What Triggered Embecta's Recent Stock Plunge and Analyst Downgrades - Kavout
Embecta (EMBC) Hit With A Sharp Target Cut As Medtech Sentiment Weakens - Insider Monkey
Why Embecta stock plummeted today - MSN
Embecta Corp. (EMBC) Q1 2026 Earnings: EPS Misses Expectations as Revenue Data Remains Unavailable - newsline.com
Embecta Corp. (EMBC) Holds Steady at $3.32 as Traders Await Clear DirectionRounding Bottom - thelegaladvocate.com
Embecta Corp. (EMBC) Stalls Near Support Amid Low-Volume TradingVolume Oscillator - newsline.com
EMBC SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Carroll County Mirror-Democrat
Embecta closes $200M Owen Mumford acquisition - NJBIZ
Embecta Corp. (EMBC) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Embecta Corp stock (US29082K1051): analyst price cut and sliding share price put diabetes specialist - AD HOC NEWS
EMBC Maintained by B of A Securities -- Price Target Lowered to $3.00 - GuruFocus
Forvis Mazars advises on sale of Owen Mumford to US-listed Embecta - Accountancy Today
Embecta Price Target Cut to $3.00/Share From $11.00 by B of A Securities - Moomoo
Embecta closes Owen Mumford acquisition for up to $201M - MedTech Dive
Embecta Is Maintained at Underperform by B of A Securities - Moomoo
Embecta completes Owen Mumford acquisition - Drug Delivery Business
BofA Securities Adjusts Price Target on Embecta to $3 From $11 - Moomoo
Embecta Corp (EMBC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.23%
자본화:
|
볼륨(24시간):